Stefania Bellone

7PUBLICATIONS
41CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 14, 2026
A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

|Sep 27, 2025
Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor.

Cem Demirkiran, Stefania Bellone, Victoria M Ettorre

|Aug 27, 2025
Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas.

Niccolò G Santin, Namrata Sethi, Stefania Bellone

|Apr 29, 2025
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.

Michelle Greenman, Cem Demirkiran, Stefania Bellone

|Apr 09, 2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147).

Sangini S Sheth, Ji Eun Oh, Stefania Bellone

|Sep 07, 2023
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.

Levent Mutlu, Diego D Manavella, Stefania Bellone

Pageof 2

Frequent Collaborators

7 joint publications

Alessandro D Santin

6 joint publications

Blair McNamara

4 joint publications

Tobias Max Philipp Hartwich

4 joint publications

Elena S Ratner